# Clinician Safety Reviewer — clinician_claude

**Model:** anthropic/claude-sonnet-4-20250514  
**Date:** 2026-04-15  
**Tokens:** 9642 input / 2205 output  
**Duration:** 51.3s  

---

# Clinician Safety Reviewer — Safety Review

## Executive Summary
DNLI-I-0001 demonstrates a high-risk safety profile with universal IRRs (100% incidence, 442 events), including one anaphylactic reaction, and concerning immunogenicity (95% ADA-positive, 60% neutralizing). While no hepatotoxicity or persistent QTcF prolongation has emerged, the severe IRR burden and rising ADA rates require immediate protocol modifications and enhanced safety monitoring before continuing enrollment.

## Findings

### Universal IRR with Anaphylaxis Signal
- **Priority:** CRITICAL
- **Confidence:** HIGH
- **Section(s):** 5.2, 5.3
- **Description:** 100% IRR incidence (442 total events) with 75% moderate-severe reactions and one anaphylactic reaction (participant 0017-9004, Grade 3 SAE). IRR frequency appears dose-dependent with B1 cohort showing highest severity (100% moderate-severe vs 70-75% other cohorts).
- **Recommendation:** Implement mandatory anaphylaxis protocol at all sites, consider IRR severity scoring system, and evaluate maximum tolerated dose threshold. Require epinephrine availability and intensivist backup for all future infusions.

### High Immunogenicity Compromising Efficacy
- **Priority:** HIGH
- **Confidence:** HIGH
- **Section(s):** 4.2
- **Description:** 95% ADA positivity (19/20) with 60% neutralizing antibodies. Seven participants required DEC-mandated dose adjustments due to immunogenicity. High sustained titers noted in key participants (0016-9004, 2065-9002, 0016-9003).
- **Recommendation:** Implement immunosuppressive premedication strategy (consider rituximab/methotrexate protocols used in other enzyme therapies). Establish ADA titer thresholds for dose modifications and evaluate drug exposure-response relationships.

### Concerning Hypoxemia Events
- **Priority:** HIGH
- **Confidence:** MODERATE
- **Section(s):** 5.2, 8
- **Description:** SpO2 <92% in 2/20 participants (10%), including participant 0017-9004 with hypoxia SAE (Day 388, Grade 3). Hypoxia events cluster in B1 cohort (1/2 participants) and appear temporally related to IRRs.
- **Recommendation:** Mandate continuous pulse oximetry during infusions and 4-hour post-infusion monitoring. Establish SpO2 <95% as infusion stop criterion and require pulmonology consultation for recurrent events.

### Pediatric Age-Related Safety Concerns
- **Priority:** HIGH
- **Confidence:** HIGH
- **Section(s):** 2.1, 5.3
- **Description:** Youngest cohort (B1, mean age 27 months) shows highest IRR severity (100% moderate-severe) and both participants experienced SAEs. Age range spans 27-198 months with different risk profiles by development stage.
- **Recommendation:** Establish age-specific safety monitoring protocols and consider minimum age restriction (>36 months). Implement pediatric critical care consultation requirement for participants <48 months.

### High SAE Burden with Disease Confounding
- **Priority:** MEDIUM
- **Confidence:** MODERATE
- **Section(s):** 5.3
- **Description:** 65% SAE incidence (13/20) with only 1 drug-related (5%). However, infectious SAEs (MRSA bacteremia, pneumonia, Staph aureus) may reflect immunocompromise from underlying disease or drug effect. Neurological SAEs (seizure, cognitive disorder, dyskinesia) complicate disease progression assessment.
- **Recommendation:** Implement infectious disease monitoring protocol with regular cultures. Establish baseline neurological assessment battery to differentiate drug effects from disease progression. Consider infectious prophylaxis in high-risk participants.

### QTcF Prolongation During IRRs
- **Priority:** MEDIUM
- **Confidence:** MODERATE
- **Section(s):** 7
- **Description:** QTcF >450ms in 3/20 participants (15%) during IRR events with tachycardia. While episodes were transient and non-persistent, combination of tachycardia + QTcF prolongation during cytokine release suggests cardiac stress.
- **Recommendation:** Implement cardiac monitoring during all infusions with 12-lead ECGs at 15-minute intervals during IRRs. Consider cardiology consultation for recurrent QTcF >460ms or any QTcF >480ms.

### Poor Dose Compliance from IRR-Related Interruptions
- **Priority:** MEDIUM
- **Confidence:** HIGH
- **Section(s):** 3.2, 4.1
- **Description:** 60% of participants experienced dose interruptions (12/20), with B1 cohort at 100%. Compliance ranges 91-96% but IRR-related interruptions may compromise efficacy while maintaining toxicity exposure.
- **Recommendation:** Develop standardized IRR management algorithm with clear restart criteria. Consider split-dose regimens or extended infusion times (>4 hours) to reduce IRR severity and improve compliance.

### Inadequate IRR Premedication Strategy
- **Priority:** MEDIUM
- **Confidence:** MODERATE
- **Section(s):** 5.2
- **Description:** Despite 442 IRR events and universal occurrence, current premedication strategy appears insufficient. Pyrexia in 80% (16/20) and vomiting in 85% (17/20) suggest inadequate prophylaxis.
- **Recommendation:** Escalate premedication protocol: add H1/H2 antihistamines, corticosteroids, and consider montelukast. Implement IV access protocols and mandatory pre-hydration. Evaluate tocilizumab for refractory cases.

### Missing Long-term Cardiac Safety Data
- **Priority:** MEDIUM
- **Confidence:** LOW
- **Section(s):** 7
- **Description:** ECG monitoring appears limited to infusion periods. With repeated IRR-related cardiac stress over 52+ weeks median exposure, cumulative cardiac effects are unknown. No echocardiographic data presented.
- **Recommendation:** Implement quarterly echocardiograms and 24-hour Holter monitoring every 6 months. Add BNP/troponin to safety labs. Consider cardiac MRI for participants with >50 IRR episodes.

### Inadequate Safety Data Granularity
- **Priority:** LOW
- **Confidence:** HIGH
- **Section(s):** Multiple
- **Description:** Safety data lacks temporal relationship analysis (IRR severity vs dose escalation timing), dose-response relationships for AEs, and detailed IRR management interventions. Synthetic trend plots limit interpretability.
- **Recommendation:** Provide individual participant safety narratives for SAE cases, IRR episode details with interventions, and correlation analysis between ADA titers, IRR severity, and dose levels.

### Screen Failure Hepatotoxicity Signal
- **Priority:** LOW
- **Confidence:** LOW
- **Section(s):** 1.3
- **Description:** One screen failure (2064-9001) for ALT/AST >3×ULN suggests potential pre-clinical hepatotoxicity risk, though could reflect underlying disease or concurrent medications.
- **Recommendation:** Review screen failure laboratory values and medical history. Consider enhanced hepatic monitoring in first 12 weeks of treatment and exclude participants with baseline ALT >2×ULN.

## Risk Assessment Matrix
| Domain | Risk Level | Key Signal | Action Required |
|--------|-----------|------------|-----------------|
| IRR/Anaphylaxis | CRITICAL | 100% IRR, 1 anaphylaxis | Enhanced resuscitation protocols |
| Immunogenicity | HIGH | 95% ADA, 60% neutralizing | Immunosuppressive strategy |
| Respiratory | HIGH | Hypoxia SAEs, SpO2 events | Continuous monitoring |
| Cardiac | MEDIUM | QTcF prolongation + tachycardia | Enhanced cardiac surveillance |
| Infectious | MEDIUM | Multiple infectious SAEs | ID monitoring protocol |
| Hepatic | LOW | Clean eDISH, 1 screen failure | Continue standard monitoring |
| Neurological | MEDIUM | Disease vs drug effects unclear | Baseline assessment battery |

## Summary Recommendations

1. **Implement CRITICAL safety protocol modifications**: Mandate anaphylaxis protocols, continuous pulse oximetry, and intensivist backup at all sites before enrolling additional participants.

2. **Develop immunosuppressive premedication strategy**: Add rituximab/methotrexate protocols to reduce ADA formation and improve drug tolerability, similar to other enzyme replacement therapies.

3. **Establish age-specific safety monitoring**: Implement enhanced monitoring for participants <48 months with pediatric critical care consultation requirements given highest IRR severity in youngest cohort.

4. **Enhance IRR management protocols**: Develop standardized prophylaxis (H1/H2 blockers, steroids) and consider extended infusion times or split dosing to improve the 91-96% compliance compromised by universal IRR burden.

5. **Implement comprehensive cardiac monitoring**: Add quarterly echocardiograms and continuous ECG monitoring during infusions given repeated cardiac stress from 442 IRR events over extended treatment periods.